

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 16, 2019

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 17, 2018 meeting
- IV. Secretary's report
- V. New Business
 - A. Proposed protocol for dupilumab (Dupixent[®])
 - B. Proposed Protocol for cannabidiol (Epidiolex[®])
 - C. Proposed protocol for pregabalin (Lyrica[®])
- VI. Informational Highlight/Report
 - A. Opioid utilization review (October 2015 – September 2018)
 - B. Informational Highlights/Reports
 1. Molina/NJ HMO 3rd Quarter 2018 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered/Antiviral drugs by amount paid
 4. Medication information:
 - (a) FDA considers requiring co-prescribing overdose antidote to go along with opioids
 - (b) Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment
 - (c) Prescriptions – and overdoses – are skyrocketing for anti-anxiety drugs that make opioids even more lethal
 - (d) FDA provides update on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan
- VII. Referenced Material
 - A. Proposed pancreatic enzymes protocol